Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 846

1.
3.

Phase I studies of ZD1839 in patients with common solid tumors.

Lorusso PM.

Semin Oncol. 2003 Feb;30(1 Suppl 1):21-9. Review.

PMID:
12644981
4.

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J.

J Clin Oncol. 2003 Jun 15;21(12):2237-46. Epub 2003 May 14. Erratum in: J Clin Oncol. 2004 Dec 1;22(23):4863.

PMID:
12748244
5.

United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets.

Cohen MH, Williams GA, Sridhara R, Chen G, McGuinn WD Jr, Morse D, Abraham S, Rahman A, Liang C, Lostritto R, Baird A, Pazdur R.

Clin Cancer Res. 2004 Feb 15;10(4):1212-8.

6.
7.

Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.

Adis International Ltd.

Drugs R D. 2003;4(4):243-8.

PMID:
12848590
8.
9.

ZD1839 (Iressa): what's in it for the patient?

Natale RB, Zaretsky SL.

Oncologist. 2002;7 Suppl 4:25-30. Review.

10.
11.

[IRESSA in the treatment of advanced non-small-cell lung cancer patients who failed to respond previous chemotherapy].

Wang B, Zhang XR, Chu DT.

Zhonghua Zhong Liu Za Zhi. 2004 Dec;26(12):742-5. Chinese.

PMID:
15733394
12.
13.

New directions for ZD1839 in the treatment of solid tumors.

Schiller JH.

Semin Oncol. 2003 Feb;30(1 Suppl 1):49-55. Review.

PMID:
12644984
14.

FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets.

Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R.

Oncologist. 2003;8(4):303-6.

15.

Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer.

Ross HJ, Blumenschein GR Jr, Aisner J, Damjanov N, Dowlati A, Garst J, Rigas JR, Smylie M, Hassani H, Allen KE, Leopold L, Zaks TZ, Shepherd FA.

Clin Cancer Res. 2010 Mar 15;16(6):1938-49. doi: 10.1158/1078-0432.CCR-08-3328. Epub 2010 Mar 9.

16.

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH.

J Clin Oncol. 2004 Mar 1;22(5):777-84.

PMID:
14990632
17.

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH.

J Clin Oncol. 2004 Mar 1;22(5):785-94.

PMID:
14990633
18.

Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors.

LoRusso PM, Herbst RS, Rischin D, Ranson M, Calvert H, Raymond E, Kieback D, Kaye S, Gianni L, Harris A, Bjork T, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Feyereislova A, Heyes A, Averbuch SD, Ochs J, Baselga J.

Clin Cancer Res. 2003 Jun;9(6):2040-8.

19.
20.

Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.

Jänne PA, Gurubhagavatula S, Yeap BY, Lucca J, Ostler P, Skarin AT, Fidias P, Lynch TJ, Johnson BE.

Lung Cancer. 2004 May;44(2):221-30.

PMID:
15084387

Supplemental Content

Support Center